Clotrimazole/betamethasone dipropionate

Clotrimazole/betamethasone dipropionate, sold under the brand name Lotrisone among others, is a topical medication used for the treatment of fungal infections of the feet, groin, and body in people 17 years of age and older.[1][2] It is a combination of clotrimazole and betamethasone dipropionate.[1] It is applied to the skin.[1]

Clotrimazole/betamethasone dipropionate
Combination of
ClotrimazoleAzole antifungal
Betamethasone dipropionateCorticosteroid
Clinical data
Trade namesLotrisone
AHFS/Drugs.comMonograph
License data
Routes of
administration		Topical
ATC code
Legal status
Legal status
Identifiers
KEGG

Common side effects include paresthesia, rash, edema, and secondary infections.[1]

In 2020, it was the 308th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[3][4]

Medical uses

Clotrimazole/betamethasone dipropionate is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in people 17 years of age and older.[1]

Society and culture

Clotrimazole/betamethasone dipropionate cream was approved for medical use in the United States in July 1984,[5] and the lotion was approved for use in the United States in December 2000.[6]

References
  1. "Lotrisone- clotrimazole and betamethasone dipropionate cream". DailyMed. 14 June 2019. Retrieved 13 April 2020.
  2. Greenberg HL, Shwayder TA, Bieszk N, Fivenson DP (2002). "Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections". Pediatric Dermatology. 19 (1): 78–81. doi:10.1046/j.1525-1470.2002.00027.x. PMID 11860579. S2CID 23472426.
  3. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  4. "Betamethasone; Clotrimazole - Drug Usage Statistics". ClinCalc. 23 December 2019. Retrieved 7 October 2022.
  5. "Lotrisone: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 13 April 2020.
  6. "Drug Approval Package: Lotrisone (Clotrizazole & Betamethasone Dipropionate) NDA #020010". U.S. Food and Drug Administration (FDA). 8 September 2004. Retrieved 13 April 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.